“The CHMP’s positive opinion of our new tablet formulation of BRUKINSA is an important step toward bringing this thoughtful, patient-centered innovation to people facing certain B-cell cancers ...

Longer Acting GLP-1 Receptor Agonists and the Potential for Improved Cardiovascular Outcomes A Review of Current Literature ...

Three GLP-1s, liraglutide, semaglutide and dulaglutide, have now been approved to reduce the risks of cardiovascular disease. Several studies indicate GLP-1s may have even farther-ranging benefits.

Anum Saeed, M.D., from the University of Pittsburgh, and colleagues compared mortality and cardiovascular event risks in patients treated with semaglutide versus empagliflozin and dulaglutide ...

Lenovo's Legion Tab is a compact 8-inch tablet packed with a high-end processor, a vibrant 165Hz display, and smart, user-focused design features.